Skip to main content
Clinical Trials/NCT01866254
NCT01866254
Completed
Early Phase 1

Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries

Grace Shih, MD1 site in 1 country45 target enrollmentMay 2013

Overview

Phase
Early Phase 1
Intervention
Hydromorphone
Conditions
Pain
Sponsor
Grace Shih, MD
Enrollment
45
Locations
1
Primary Endpoint
Change in Pain Scores
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to determine if intrathecal hydromorphone will relieve pain as well as intrathecal morphine after cesarean delivery, with fewer side effects.

Detailed Description

Intrathecal morphine has long been the standard pain medication used in cesarean sections. Since some patients cannot tolerate morphine, hydromorphone may be an acceptable alternative. Intrathecal Intrathecal hydromorphone has been shown to be effective at treating post cesarean section pain and possibly with less side effects than morphine. One side effect of morphine is respiratory depression occurring hours after the start of morphine use. Respiratory depression occurs when air being taken into the lungs is less than normal, leading to a lower amount of oxygen and carbon dioxide being exchanged in the blood stream. Because hydromorphone dosages are lower and it has a quicker onset of action than morphine, it is believed that the use of hydromorphone should decrease the possibility of delayed respiratory depression.

Registry
clinicaltrials.gov
Start Date
May 2013
End Date
October 22, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Grace Shih, MD
Responsible Party
Sponsor Investigator
Principal Investigator

Grace Shih, MD

Associate Professor

University of Kansas Medical Center

Eligibility Criteria

Inclusion Criteria

  • Scheduled for elective Cesarean sections under spinal anesthesia or combined spinal anesthesia
  • ASA status of I-III
  • BMI \< 40
  • Able to understand and sign informed consent

Exclusion Criteria

  • Severe pre-eclampsia
  • Conversion to general anesthetic
  • History of chronic opioid use
  • Allergy to morphine, or hydromorphone
  • Hyperemesis gravidarum
  • Emergency case
  • Patients who have an infection at the intended site of spinal insertion

Arms & Interventions

Hydromorphone

100 mg, intrathecal administration

Intervention: Hydromorphone

Morphine

200 mg, intrathecal administration

Intervention: Morphine

Outcomes

Primary Outcomes

Change in Pain Scores

Time Frame: from Baseline to 24 Hours

Pain scores to be measured using the verbal response scale (VRS). The VRS pain score is measured on a scale of 0-10 with 0 representing absolutely no pain and 10 representing worst pain imaginable

Secondary Outcomes

  • Number of Participants with Adverse Events (AEs)(up to 24 Hours)

Study Sites (1)

Loading locations...

Similar Trials